Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 133 participants.

Also called NCT03788590

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 133 participants (planned count) (from the registry)
Sponsor
Ningbo Jenscare Biotechnology Co., Ltd. (from the registry)
Registry
  • NCT NCT03788590
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03788590. Allocation not applicable; no masking; primary purpose treatment. Start 2019-02-23 (anticipated); primary completion 2021-11-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System
Acronym
TAVI
Condition
Severe Aortic Stenosis
Condition
Aortic Regurgitation
Intervention (Device)
Jenscare TAVI
Lead sponsor
Ningbo Jenscare Biotechnology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03788590
Content hash
7cb10f151feb838926a60bc1a7d72cca1fb655d4aa20cb148ee7008fde5e665c